Amanda Ching-Wun Cheung, MD
Internal Medicine · Chicago
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 16 years
- University of South Carolina School of Medicine, 2010
Offices
1 location · Northwestern Medical Faculty Foundation · 4,386 clinicians in this group
Hospitals listed: Northwestern Lake Forest Hospital · Northwestern Medicine Central Dupage Hospital · Northwestern Medicine Delnor Community Hospital · Northwestern Memorial Hospital · Palos Community Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Cheung’s office at (312) 695-8108 to ask if they take your plan before you enroll.
California Medical Board record
Licence A156566 · Current
Licensed to practise in California · since 2018 · expires 2027-08-31 · University of South Carolina School of Medicine Columbia.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Illinois 036131830Licensed Physician And Surgeon · since 2012 · expires 2029-07-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Gastroenterology
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Transplant Hepatology
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 94.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Northwestern Lake Forest HospitalLake Forest, ILAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Northwestern Medicine, which runs 10 hospitalsPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.2 (11.5 to 17.3) · 434 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.169, Oct 2024 – Sep 2025
- Northwestern Medicine Central Dupage HospitalWinfield, ILAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Northwestern Medicine, which runs 10 hospitalsPatients rate it 4 of 5 · 82% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.72 (0.49 to 0.96), Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 3.46 (0 to 7.88) · 1,373 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 2.25 (0 to 5.09) · 1,458 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.445, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.288, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.355, Oct 2024 – Sep 2025
- Northwestern Medicine Delnor Community HospitalGeneva, ILAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Northwestern Medicine, which runs 10 hospitalsPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.301, Oct 2024 – Sep 2025
- Northwestern Memorial HospitalChicago, ILAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Northwestern Medicine, which runs 10 hospitalsHome of Robert H. Lurie Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.26 (0.95 to 1.56) · 17,389 cases, Jul 2022 – Jun 2024Better than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.74 (0.58 to 0.91), Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 1.71 (0 to 5.12) · 2,663 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 1.15 (0 to 3.19) · 2,766 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.609, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.392, Oct 2024 – Sep 2025
- Palos Community HospitalPalos Heights, ILAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Northwestern Medicine, which runs 10 hospitalsPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.28 (1.04 to 1.53), Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.47 (3.78 to 7.16) · 2,766 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.95 (1.53 to 2.38) · 13,524 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.543, Oct 2024 – Sep 2025
See every measure and the patient survey for Northwestern Lake Forest Hospital
Behind the star rating — Deaths: 4 better, 3 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.2 (11.5 to 17.3) · 434 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.74) · 1,201 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.08 (0.74 to 1.41) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 165.39 (107.31 to 223.46) · 44 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 118 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 126 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 5.7 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.1 · 524 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.2 · 199 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 2,684 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.38) · 7,237 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,490 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.92 (1.8 to 6.04) · 1,119 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 458 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.84 (0.3 to 3.39) · 1,036 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.23 (0 to 15.05) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.97 (0.19 to 7.75) · 438 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 254 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.28 (0.61 to 1.95) · 5,995 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 80 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.906 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.172 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.312 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 92 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 623 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -13.8 · 97 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -15 · 632 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -30 · 529 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 507 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.8 to 7.1) · 434 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.2 · 74 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.4 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.3 to 14.7) · 3,079 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 775 cases | No different | Jan 2024 – Dec 2024 |
What patients said (757 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 63% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Northwestern Medicine Central Dupage Hospital
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 7 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.72 (0.49 to 0.96) | Better | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 3.46 (0 to 7.88) · 1,373 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 2.25 (0 to 5.09) · 1,458 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.445 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.288 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.355 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.13 to 1.8) · 2,505 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 154.95 (106.25 to 203.64) · 107 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.4 · 205 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 183 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 263 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 881 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 702 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11 · 595 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 5,533 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 12,244 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.03 to 0.38) · 12,922 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.35 (0.71 to 3.99) · 3,121 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.88 (0 to 2.15) · 1,469 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.32 (1.05 to 3.59) · 2,633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.45 (0.06 to 2.84) · 801 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.96 (0.45 to 1.47) · 10,662 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 55 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.305 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.63 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.4 · 329 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 1,123 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -0.4 · 300 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -16 · 1,023 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 19 · 739 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.6 · 795 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.6 (4.3 to 7.2) · 603 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12 (9.9 to 14.4) · 603 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 8.6 · 198 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 212 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.7 to 14.5) · 4,388 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 997 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,496 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 62% |
| "YES", patients would definitely recommend the hospital | 82% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Northwestern Medicine Delnor Community Hospital
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.301 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.81 (0 to 1.78) · 1,249 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.69 (0.34 to 1.03) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.28 (84.18 to 194.38) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 133 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.1 · 519 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 464 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 220 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 2,882 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,078 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.48) · 7,044 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.83 (0.75 to 4.92) · 1,201 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.24) · 383 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.64 (1.1 to 4.18) · 1,077 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.64 (0 to 13.53) · 393 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.29 (0.36 to 8.21) · 375 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.15) · 340 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 5,475 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 26 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.34 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.78 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.3 · 130 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 587 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -22.7 · 118 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.4 · 590 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -19 · 475 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.1 · 547 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.2 (3 to 5.9) · 364 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.3 (10.6 to 16.6) · 364 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 28 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.2 · 145 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11 (8.8 to 13.9) · 2,891 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 489 cases | No different | Jan 2024 – Dec 2024 |
What patients said (748 patients answered, 31% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 80% |
| Staff "always" explained new medications | 81% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 65% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 52% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Northwestern Memorial Hospital
Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 5 better, 3 the same, 0 worse of 8 measures. Readmissions: 0 better, 8 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.26 (0.95 to 1.56) · 17,389 cases | Worse | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.74 (0.58 to 0.91) | Better | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 1.71 (0 to 5.12) · 2,663 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 1.15 (0 to 3.19) · 2,766 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.609 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.392 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0.25 to 1.55) · 4,931 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 146.95 (119.26 to 174.63) · 403 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 168 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 163 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 5.7 · 946 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 7.9 · 833 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 513 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.2 · 6,861 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.3) · 17,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.32 (0.17 to 0.48) · 20,121 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.81 (1.6 to 4.02) · 6,294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.65 (0 to 1.73) · 2,722 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.45 (0.49 to 2.41) · 5,017 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.2 (0.98 to 3.41) · 1,549 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 345 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.828 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.742 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.897 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 1,270 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 31.2 · 189 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -6.1 · 1,115 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 862 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 949 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.4 (3.1 to 6.5) · 349 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (7.3 to 12.7) · 349 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 165 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.5 · 259 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.2 (9.4 to 13.4) · 8,056 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1) · 1,959 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,820 patients answered, 23% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 63% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Palos Community Hospital
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 7 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.28 (1.04 to 1.53) | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.47 (3.78 to 7.16) · 2,766 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.95 (1.53 to 2.38) · 13,524 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.543 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.42 to 2.05) · 2,758 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 156.31 (114.32 to 198.29) · 157 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 64 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.1 · 422 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.1 · 369 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 1,082 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 1,420 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.6 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 5,496 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0.01 to 0.35) · 15,082 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.35 (0.18 to 0.51) · 15,906 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.95) · 841 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.34 (0.02 to 2.65) · 2,503 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.69 (0 to 10.3) · 810 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.78 (0.66 to 6.91) · 791 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.06 (0.66 to 3.46) · 684 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 130 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.496 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.049 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.812 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.491 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.9 · 396 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 1,325 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 7.4 · 346 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 0.4 · 1,260 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 5.7 · 1,459 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 1,645 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.8 (3 to 7.5) · 60 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.3 (6.3 to 13.5) · 60 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.2 · 131 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.5 · 533 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.7 (9.3 to 14.7) · 2,297 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 778 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,030 patients answered, 27% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$45,074
Medicare paid this office $45,074 for 278 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $8,612 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $5,695 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $4,347 | $66 |
| Long return visit (40+ min) | 16 | $4,195 | $150 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 37 | $4,051 | $109 |
See all 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $8,612 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $5,695 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $4,347 | $66 |
| Long return visit (40+ min) | 16 | $4,195 | $150 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 37 | $4,051 | $109 |
| New patient visit (45+ min) | 21 | $2,923 | $139 |
| Return visit (30+ min) | 24 | $2,824 | $94 |
| Return visit (30+ min) | 24 | $1,913 | $77 |
| Measurement of liver stiffness | 61 | $1,459 | $24 |
| Long return visit (40+ min) | 11 | $1,457 | $112 |
| Hospital discharge day management, 30 minutes or less | 11 | $826 | $69 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 37 | $748 | $14 |
| Measurement of liver stiffness | 76 | $624 | $8 |
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 30 | More than 56% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of large bowel using a flexible endoscope | 57 | 21 | 19 | – | – | – |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 42 | 13 | 16 | – | – | – |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 16 | 20 | 15 | – | – | – |
| Tying of dilated veins of stomach and/or esophagus using a flexible endoscope | 16 | – | – | – | – | – |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
278 Original Medicare patients in 2024. Average age 70 · Under 65 14% · 85 and older 4% · Women 53% · Also on Medicaid 22% · Health risk score 2.17. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Diabetes 45% · Coronary heart disease 40% · Chronic kidney disease 40% · Heart failure 32% · Depression 26% · Atrial fibrillation 23% · Cancer 17% · COPD 10% · Stroke 10% · Dementia 9%.
The office billed $188,795, Medicare allowed $57,463 and paid $45,074; for 608 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 278 | 608 | 70 | 2.17 | $188,795 | $45,074 |
| 2023 | 201 | 417 | 70 | 2.49 | $128,250 | $35,267 |
| 2022 | 144 | 342 | 68 | 2.28 | $107,172 | $29,364 |
| 2021 | 294 | 760 | 68 | 2.18 | $495,474 | $72,984 |
| 2020 | 252 | 725 | 68 | 2.22 | $522,993 | $69,188 |
| 2019 | 277 | 655 | 68 | 2.14 | $544,892 | $71,837 |
| 2018 | 98 | 199 | 68 | 2.06 | $169,997 | $22,643 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $6,521 | $100 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,179 | $144 |
| Return visit (30+ min) | 22 | $3,450 | $105 |
| Return visit (30+ min) | 35 | $2,936 | $77 |
| Long return visit (40+ min) | 17 | $2,904 | $108 |
| Long return visit (40+ min) | 13 | $2,897 | $138 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,689 | $67 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,890 | $111 |
| Measurement of liver stiffness | 67 | $564 | $8 |
| Measurement of liver stiffness | 16 | $390 | $24 |
2022: 10 services
| Return visit (30+ min) | 45 | $4,376 | $80 |
| Long return visit (40+ min) | 22 | $3,867 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $3,565 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $3,066 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,346 | $168 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $2,070 | $115 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,334 | $78 |
| Return visit (30+ min) | 11 | $1,169 | $106 |
| Hospital discharge day management, 30 minutes or less | 11 | $789 | $61 |
| Measurement of liver stiffness | 25 | $225 | $9 |
2021: 12 services
| Return visit (30+ min) | 123 | $15,890 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $12,212 | $95 |
| Long return visit (40+ min) | 53 | $7,435 | $106 |
| New patient visit (60+ min) | 27 | $5,088 | $188 |
| Long return visit (40+ min) | 14 | $4,721 | $131 |
| New patient visit (45+ min) | 29 | $4,070 | $140 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 15 | $3,481 | $232 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,322 | $185 |
| Biopsy of large bowel using a flexible endoscope | 19 | $1,798 | $95 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,689 | $106 |
| Measurement of liver stiffness | 101 | $814 | $8 |
| Telehealth originating site facility fee | 19 | $423 | $21 |
2020: 9 services
| Long return visit (40+ min) | 116 | $24,276 | $103 |
| New patient visit (60+ min) | 64 | $9,732 | $152 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $7,435 | $97 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 20 | $4,738 | $237 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,285 | $186 |
| Biopsy of large bowel using a flexible endoscope | 20 | $2,567 | $122 |
| Telehealth originating site facility fee | 49 | $1,502 | $22 |
| Measurement of liver stiffness | 90 | $975 | $11 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $903 | $69 |
2019: 15 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $13,466 | $93 |
| Long return visit (40+ min) | 65 | $12,716 | $106 |
| New patient visit (60+ min) | 48 | $7,047 | $147 |
| Biopsy of large bowel using a flexible endoscope | 38 | $4,819 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,253 | $177 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 16 | $3,361 | $210 |
| Tying of dilated veins of stomach and/or esophagus using a flexible endoscope | 12 | $3,221 | $201 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 14 | $2,831 | $202 |
| Biopsy of large bowel using a flexible endoscope | 16 | $2,551 | $142 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 26 | $2,410 | $86 |
| Hospital discharge day management, more than 30 minutes | 20 | $2,109 | $96 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,190 | $108 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,146 | $82 |
| Measurement of liver stiffness | 33 | $415 | $13 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 20 | $106 | $5 |
2018: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $4,491 | $94 |
| New patient visit (60+ min) | 14 | $2,086 | $149 |
| Long return visit (40+ min) | 11 | $1,597 | $114 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $826 | $75 |
Medicaid work
$4,183 in 2021
Medicaid paid $4,183 for 115 billed services this clinician did in 2021, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 115 | $4,183 |
| 2021 | 115 | 1 | 20 | $4,183 |
| 2020 | 72 | 2 | 13 | $5,032 |
| 2019 | 131 | 1 | 19 | $4,747 |
| 2018 | 43 | 1 | 13 | $1,264 |
See the largest Medicaid services in earlier years
2020
| Long return visit (40+ min) | 26 | $2,854 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 46 | $2,178 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 131 | $4,747 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 43 | $1,264 |
Drugs they prescribed that Part D paid
$344,776
Pharmacies billed $344,776 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 546) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
457 generic and 89 brand-name prescriptions · $344,776 in drug cost · 89 antibiotic prescriptions to 20 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xifaxan | 29 | $129,553 | $4,467 |
| Ursodiol | 96 | $18,510 | $193 |
| Vemlidy | 12 | $16,110 | $1,342 |
| Tacrolimus | 81 | $13,196 | $163 |
| Mycophenolate Mofetil | 13 | $1,211 | $93 |
See all 11 drugs
| Xifaxan | 29 | $129,553 | $4,467 |
| Ursodiol | 96 | $18,510 | $193 |
| Vemlidy | 12 | $16,110 | $1,342 |
| Tacrolimus | 81 | $13,196 | $163 |
| Mycophenolate Mofetil | 13 | $1,211 | $93 |
| Lactulose | 17 | $722 | $42 |
| Spironolactone | 11 | $204 | $19 |
| Carvedilol | 28 | $182 | $6 |
| Atorvastatin | 14 | $176 | $13 |
| Sulfamethoxazole-Trimethoprim | 50 | $135 | $3 |
| Prednisone | 14 | $81 | $6 |
Year by year
| 2024 | 546 | 100 | 0% (0) | 16% | $344,776 |
| 2023 | 639 | 110 | 0% (0) | 17% | $515,905 |
| 2022 | 511 | 117 | 0% (0) | None | $443,821 |
| 2021 | 666 | 106 | 0% (0) | 26% | $819,123 |
| 2020 | 693 | 122 | None | 30% | $682,917 |
| 2019 | 319 | 98 | 0% (0) | 44% | $661,651 |
| 2018 | 65 | 43 | 0% (0) | 35% | $146,372 |
| 2017 | 138 | 29 | None | 23% | $129,148 |
| 2016 | 146 | 28 | 8% (11) | 28% | $30,709 |
| 2015 | 112 | 46 | None | 29% | $22,608 |
| 2014 | 214 | 57 | None | 19% | $36,907 |
| 2013 | 266 | 57 | 5% (12) | 17% | $21,618 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Xifaxan | 25 | $124,941 | $4,998 |
| Vemlidy | 14 | $23,689 | $1,692 |
| Ursodiol | 54 | $17,617 | $326 |
| Tacrolimus | 89 | $15,931 | $179 |
| Everolimus | 12 | $10,612 | $884 |
| Mycophenolate Mofetil | 20 | $4,400 | $220 |
| Azathioprine | 13 | $2,611 | $201 |
| Lactulose | 16 | $1,072 | $67 |
| Spironolactone | 15 | $955 | $64 |
| Sulfamethoxazole-Trimethoprim | 92 | $527 | $6 |
| Pantoprazole | 16 | $461 | $29 |
| Pravastatin | 13 | $276 | $21 |
| Carvedilol | 17 | $201 | $12 |
| Furosemide | 18 | $188 | $10 |
| Atorvastatin | 11 | $185 | $17 |
| Prednisone | 22 | $181 | $8 |
| Metoprolol | 11 | $113 | $10 |
2022: 15 drugs
| Xifaxan | 27 | $97,884 | $3,625 |
| Vemlidy | 25 | $38,998 | $1,560 |
| Ursodiol | 51 | $16,427 | $322 |
| Tacrolimus | 40 | $9,104 | $228 |
| Tenofovir Disoproxil | 19 | $1,859 | $98 |
| Azathioprine | 17 | $1,465 | $86 |
| Lactulose | 15 | $988 | $66 |
| Spironolactone | 17 | $798 | $47 |
| Pantoprazole | 16 | $316 | $20 |
| Rosuvastatin | 15 | $206 | $14 |
| Furosemide | 13 | $180 | $14 |
| Sulfamethoxazole-Trimethoprim | 40 | $165 | $4 |
| Prednisone | 11 | $124 | $11 |
| Amlodipine Besylate | 13 | $110 | $8 |
| Losartan | 11 | $23 | $2 |
2021: 21 drugs
| Ocaliva | 28 | $290,759 | $10,384 |
| Xifaxan | 33 | $94,878 | $2,875 |
| Vemlidy | 47 | $67,556 | $1,437 |
| Sirolimus | 26 | $23,014 | $885 |
| Ursodiol | 65 | $20,850 | $321 |
| Budesonide Ec | 18 | $7,446 | $414 |
| Tacrolimus | 26 | $5,357 | $206 |
| Tenofovir Disoproxil | 29 | $2,788 | $96 |
| Lactulose | 19 | $1,840 | $97 |
| Ondansetron Odt | 11 | $1,270 | $115 |
| Azathioprine | 18 | $1,265 | $70 |
| Doxepin | 14 | $1,216 | $87 |
| Propranolol | 26 | $984 | $38 |
| Pantoprazole | 26 | $338 | $13 |
| Spironolactone | 11 | $303 | $28 |
| Peg 3350-Electrolyte | 11 | $203 | $18 |
| Escitalopram | 13 | $121 | $9 |
| Furosemide | 14 | $110 | $8 |
| Sulfamethoxazole-Trimethoprim | 11 | $75 | $7 |
| Amlodipine Besylate | 31 | $56 | $2 |
| Rosuvastatin | 11 | $39 | $4 |
2020: 22 drugs
| Ocaliva | 27 | $204,698 | $7,581 |
| Xifaxan | 46 | $136,266 | $2,962 |
| Vemlidy | 42 | $55,216 | $1,315 |
| Creon | 13 | $29,934 | $2,303 |
| Ursodiol | 87 | $28,997 | $333 |
| Atovaquone | 15 | $11,602 | $773 |
| Tacrolimus | 30 | $4,817 | $161 |
| Mycophenolate Mofetil | 13 | $3,383 | $260 |
| Tenofovir Disoproxil | 14 | $2,194 | $157 |
| Lactulose | 34 | $1,593 | $47 |
| Azathioprine | 16 | $1,228 | $77 |
| Spironolactone | 11 | $306 | $28 |
| Pantoprazole | 22 | $287 | $13 |
| Peg 3350-Electrolyte | 15 | $250 | $17 |
| Levothyroxine | 20 | $221 | $11 |
| Prednisone | 12 | $152 | $13 |
| Gavilyte-G | 12 | $145 | $12 |
| Furosemide | 11 | $136 | $12 |
| Omeprazole | 12 | $88 | $7 |
| Atorvastatin | 14 | $86 | $6 |
| Sulfamethoxazole-Trimethoprim | 16 | $48 | $3 |
| Amlodipine Besylate | 13 | $36 | $3 |
2019: 9 drugs
| Mavyret | 16 | $239,217 | $14,951 |
| Ocaliva | 18 | $123,017 | $6,834 |
| Xifaxan | 20 | $50,827 | $2,541 |
| Vemlidy | 29 | $32,081 | $1,106 |
| Ursodiol | 20 | $7,097 | $355 |
| Gavilyte-N | 21 | $432 | $21 |
| Peg 3350-Electrolyte | 20 | $336 | $17 |
| Pantoprazole | 16 | $308 | $19 |
| Gavilyte-G | 11 | $138 | $13 |
2018: 1 drug
| Pantoprazole | 11 | $361 | $33 |
2017: 1 drug
| Pantoprazole | 18 | $218 | $12 |
2016: 3 drugs
| Xifaxan | 14 | $16,938 | $1,210 |
| Amitiza | 18 | $6,027 | $335 |
| Tramadol | 11 | $52 | $5 |
2015: 2 drugs
| Ursodiol | 14 | $7,011 | $501 |
| Omeprazole | 11 | $94 | $9 |
2014: 7 drugs
| Ursodiol | 18 | $5,028 | $279 |
| Spironolactone | 25 | $673 | $27 |
| Polyethylene Glycol 3350 | 13 | $334 | $26 |
| Prednisone | 24 | $240 | $10 |
| Azathioprine | 12 | $230 | $19 |
| Propranolol | 17 | $177 | $10 |
| Furosemide | 25 | $147 | $6 |
2013: 4 drugs
| Taztia Xt | 11 | $852 | $77 |
| Insulin | 14 | $253 | $18 |
| Furosemide | 20 | $210 | $10 |
| Lisinopril | 18 | $193 | $11 |
Money from drug and device companies
$43,948 in 2025
| 2025 | 5 | 36 | $39,510 | $43,948 |
| 2024 | 3 | 10 | $14,644 | $16,488 |
| 2023 | 4 | 10 | $3,300 | $3,863 |
| 2022 | 1 | 1 | None | $38 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novo Nordisk | Wegovy | $39,278 | 26 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $3,985 | 7 payments
|
| Eton Pharmaceuticals | Galzin | $500 | 1 payment
|
| Mallinckrodt Hospital Products | Terlivaz | $111 | 1 payment
|
| Orphalan | Cuvrior | $75 | 1 payment
|
See all 36 published payments
| Novo Nordisk | Travel · 2025-11-20 | Wegovy | $180 |
| Novo Nordisk | Travel · 2025-11-20 | Wegovy | $117 |
| Novo Nordisk | Paid to speak or teach · 2025-11-20 | Wegovy | $8,046 |
| Novo Nordisk | Meals · 2025-11-20 | Wegovy | $137 |
| Novo Nordisk | Travel · 2025-11-19 | Wegovy | $114 |
| Novo Nordisk | Paid to speak or teach · 2025-11-19 | Wegovy | $8,046 |
| Novo Nordisk | Travel · 2025-11-19 | Wegovy | $797 |
| Novo Nordisk | Travel · 2025-11-19 | Wegovy | $188 |
| Novo Nordisk | Meals · 2025-11-19 | Wegovy | $142 |
| Orphalan | Meals · 2025-11-10 | Cuvrior | $75 |
| Novo Nordisk | Meals · 2025-11-09 | Wegovy | $20 |
| Novo Nordisk | Meals · 2025-11-08 | None | $120 |
| Madrigal Pharmaceuticals | Meals · 2025-11-08 | Rezdiffra | $54 |
| Novo Nordisk | Meals · 2025-11-07 | None | $62 |
| Madrigal Pharmaceuticals | Meals · 2025-11-07 | Rezdiffra | $104 |
| Madrigal Pharmaceuticals | Consulting · 2025-11-07 | Rezdiffra | $1,613 |
| Novo Nordisk | Paid to speak or teach · 2025-10-21 | Wegovy | $5,103 |
| Novo Nordisk | Meals · 2025-10-21 | Wegovy | $119 |
| Novo Nordisk | Travel · 2025-10-21 | Wegovy | $63 |
| Novo Nordisk | Travel · 2025-10-10 | Wegovy | $221 |
| Novo Nordisk | Travel · 2025-10-10 | Wegovy | $459 |
| Novo Nordisk | Meals · 2025-10-10 | Wegovy | $308 |
| Novo Nordisk | Paid to speak or teach · 2025-10-10 | Wegovy | $11,520 |
| Novo Nordisk | Travel · 2025-10-10 | Wegovy | $297 |
| Madrigal Pharmaceuticals | Meals · 2025-09-26 | Rezdiffra | $23 |
| Novo Nordisk | Meals · 2025-08-13 | Wegovy | $119 |
| Novo Nordisk | Meals · 2025-08-03 | None | $44 |
| Mallinckrodt Hospital Products | Meals · 2025-08-03 | Terlivaz | $111 |
| Madrigal Pharmaceuticals | Meals · 2025-06-17 | Rezdiffra | $114 |
| Novo Nordisk | Meals · 2025-06-10 | None | $64 |
| Novo Nordisk | Meals · 2025-06-10 | None | $119 |
| Madrigal Pharmaceuticals | Consulting · 2025-06-09 | Rezdiffra | $1,935 |
| Eton Pharmaceuticals | Consulting · 2025-05-09 | Galzin | $500 |
| Madrigal Pharmaceuticals | Meals · 2025-03-18 | Rezdiffra | $142 |
| Novo Nordisk | Meals · 2025-03-12 | None | $125 |
| Novo Nordisk | Consulting · 2025-02-10 | None | $2,748 |
See earlier years (2024, 2023, 2022)
2024: $16,488
| Novo Nordisk | None | $12,828 | 8 payments
|
| Orphalan | Cuvrior | $3,600 | 1 payment
|
| Madrigal Pharmaceuticals | Resmetirom | $60 | 1 payment
|
2023: $3,863
| Orphalan | Cuvrior | $3,506 | 3 payments
|
| Novo Nordisk | Wegovy | $230 | 3 payments
|
| Alexion Pharmaceuticals | None | $68 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $58 | 2 payments
|
2022: $38
| Novo Nordisk | None | $38 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Madrigal Pharmaceuticals · A 52-Week, Phase 3, Open-Label Extension Study, With A Double-Blind Lead-in, To Evaluate Safety and Biomarkers of Resmetirom (Mgl-3196) in Patients With Non-Alcoholic Fatty Liver Disease (Nafld), Maestro-Nafld-Open-Label-Extension (Maestro-Nafld-Ole) · 2025 | Their institution | $157,881 |
| Madrigal Pharmaceuticals · A 52-Week, Phase 3, Open-Label Extension Study, With A Double-Blind Lead-in, To Evaluate Safety and Biomarkers of Resmetirom (Mgl-3196) in Patients With Non-Alcoholic Fatty Liver Disease (Nafld), Maestro-Nafld-Open-Label-Extension (Maestro-Nafld-Ole) · 2024 | Their institution | $84,361 |
| Madrigal Pharmaceuticals · A 52week Phase 3 Openlabel Extension Study With A Doubleblind Leadin To Evaluate Safety and Biomarkers of Resmetirom Mgl3196 in Patients With Nonalcoholic Fatty Liver Disease Nafld Maestronafldopenlabelextension Maestronafldole · 2025 | Their institution | $31,376 |
| Bausch Health US, LLC · Study To Assess Rifaximin Soluble Solid Dispersion (Ssd) for the Delay of Encephalopathy Decompensation in Cirrhosis (Red-C-3132) · 2024 | Their institution | $28,625 |
| Madrigal Pharmaceuticals · A 52week Phase 3 Openlabel Extension Study With A Doubleblind Leadin To Evaluate Safety and Biomarkers of Resmetirom Mgl3196 in Patients With Nonalcoholic Fatty Liver Disease Nafld Maestronafldopenlabelextension Maestronafldole · 2024 | Their institution | $24,772 |
Professional record
- NPI
- 1548585193
- Licence
- CA A156566, IL 036131830California A156566: Current · expires 2027-08-31Illinois 036131830: Active
- Trained
- University of South Carolina School of Medicine, 2010 · 16 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0008X (207RI0008X); Internal medicine (207R00000X); Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 676 N Saint Clair St Fl 19, Chicago, IL, 60611
- NPI first listed
- 2010-04-06
- NPI last updated
- 2022-02-15
- NPI record certified
- 2022-02-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 5800 Hollis St, Emeryville, CA, 94608 · 300 Pasteur Dr, Stanford, CA, 94305